Prospective Grant of Exclusive Commercialization License: The Use of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and Hepatocellular Cancer, 59708-59709 [2013-23528]

Download as PDF 59708 Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices Room 3266, Bethesda, MD 20892–7616, 301– 451–2634, maja.maric@nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting. Date: October 28–29, 2013. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate contract proposals. Place: Sheraton—Silver Spring, Cedar Room, 8777 Georgia Avenue, Silver Spring, MD 20910. Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review Officer, Scientific Review Program, DHHS/NIH/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, 301–594–3243, haririmf@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Contact Person: Victor Henriquez, Ph.D., Scientific Review Officer, DEA/SRB/NIDCR, 6701 Democracy Blvd., Room 668, Bethesda, MD 20892–4878, 301–451–2405, henriquv@ nidcr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: September 23, 2013. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–23527 Filed 9–26–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [FR Doc. 2013–23526 Filed 9–26–13; 8:45 am] Prospective Grant of Exclusive Commercialization License: The Use of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and Hepatocellular Cancer BILLING CODE 4140–01–P AGENCY: Dated: September 23, 2013. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health, HHS. ACTION: DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Dental and Craniofacial Research; Notice of Closed Meeting pmangrum on DSK3VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; Clinical Trial or Biomarker Clinical Evaluation Study Planning Grant and Clinical Trial Implementation or Biomarker Clinical Evaluation Study Cooperative Agreement Applications Review Panel. Date: October 21, 2013. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 701, 6707 Democracy Boulevard, Bethesda, MD 20892. 14:21 Sep 26, 2013 Jkt 229001 This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, indicates that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization license to practice the inventions embodied in technology family E–219– 2013/0, including U.S. patent application 61/814,010 entitled ‘‘A Novel Role of Cysteamine in Suppression of Cancer Invasion and Metastasis and Prolonging Survival of Host Through Inhibition of Matrix Metalloproteinases in Human Cancer’’ [HHS Ref. E–219–2013/0–US–01], Canadian patent application 2,813,514 entitled ‘‘Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases’’ [HHS Ref. E–219–2013/0– CA–02], South Korean patent application 10–2013–43713 entitled ‘‘Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases’’[HHS Ref. E–219–2013/0– KR–03], Australian patent application 2013205350 entitled ‘‘Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases’’ [HHS Ref. E–219–2013/0–AU–04], and Mexican patent application MX/a/2013/004423 entitled ‘‘Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases’’ [HHS Ref. E–219–2013/0– MX–05]; and all related continuing and foreign patents/patent applications for these technology families, to Raptor Pharmaceuticals, Inc. The patent rights SUMMARY: National Institutes of Health VerDate Mar<15>2010 Notice. PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive commercialization license territory may be worldwide, and the field of use may be limited to: The treatment of pancreatic cancer, breast cancer and hepatocellular carcinoma (HCC) by using compositions containing cysteamine. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 28, 2013 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive commercialization license should be directed to: David A. Lambertson, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4632; Facsimile: (301) 402– 0220; Email: lambertsond@mail.nih.gov. SUPPLEMENTARY INFORMATION: Cysteamine is a naturally occurring degradation product of the amino acid cysteine that is most commonly used for the treatment of cystinosis. The inventors on this technology have demonstrated that cysteamine suppresses the activity of matrix metalloproteinases (MMPs), enzymes that have been implicated in tumor invasion and metastasis. Importantly, administration of cysteamine was able to reduce invasion and metastasis in mouse xenograft tumor models for pancreatic cancer, prolonging the survival of the mice while having no adverse side effects. Based on these findings, cysteamine could represent a novel therapeutic treatment of cancer with fewer side-effects than current therapies. The prospective exclusive commercialization license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404 within thirty (30) days from the date of this published notice. Complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections E:\FR\FM\27SEN1.SGM 27SEN1 Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: September 20, 2013. Richard U. Rodriguez, Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–23528 Filed 9–26–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5681–N–39] Federal Property Suitable as Facilities To Assist the Homeless Office of the Assistant Secretary for Community Planning and Development, HUD. ACTION: Notice. AGENCY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for use to assist the homeless. FOR FURTHER INFORMATION CONTACT: Juanita Perry, Department of Housing and Urban Development, 451 Seventh Street SW., Room 7266, Washington, DC 20410; telephone (202) 402–3970; TTY number for the hearing- and speechimpaired (202) 708–2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 800–927–7588. SUPPLEMENTARY INFORMATION: In accordance with 24 CFR part 581 and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in National Coalition for the Homeless v. Veterans Administration, No. 88–2503– OG (D.D.C.). Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/ unavailable, and suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been pmangrum on DSK3VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 14:21 Sep 26, 2013 Jkt 229001 reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency’s needs, or (3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless. Properties listed as suitable/available will be available exclusively for homeless use for a period of 60 days from the date of this Notice. Where property is described as for ‘‘off-site use only’’ recipients of the property will be required to relocate the building to their own site at their own expense. Homeless assistance providers interested in any such property should send a written expression of interest to HHS, addressed to Theresa Ritta, Office of Enterprise Support Programs, Program Support Center, HHS, room 12–07, 5600 Fishers Lane, Rockville, MD 20857; (301) 443–2265. (This is not a toll-free number.) HHS will mail to the interested provider an application packet, which will include instructions for completing the application. In order to maximize the opportunity to utilize a suitable property, providers should submit their written expressions of interest as soon as possible. For complete details concerning the processing of applications, the reader is encouraged to refer to the interim rule governing this program, 24 CFR part 581. For properties listed as suitable/to be excess, that property may, if subsequently accepted as excess by GSA, be made available for use by the homeless in accordance with applicable law, subject to screening for other Federal use. At the appropriate time, HUD will publish the property in a Notice showing it as either suitable/ available or suitable/unavailable. For properties listed as suitable/ unavailable, the landholding agency has decided that the property cannot be declared excess or made available for use to assist the homeless, and the property will not be available. Properties listed as unsuitable will not be made available for any other purpose for 20 days from the date of this Notice. Homeless assistance providers interested in a review by HUD of the determination of unsuitability should call the toll free information line at 1– 800–927–7588 for detailed instructions or write a letter to Ann Marie Oliva at the address listed at the beginning of this Notice. Included in the request for review should be the property address (including zip code), the date of publication in the Federal Register, the PO 00000 Frm 00063 Fmt 4703 Sfmt 9990 59709 landholding agency, and the property number. For more information regarding particular properties identified in this Notice (i.e., acreage, floor plan, existing sanitary facilities, exact street address), providers should contact the appropriate landholding agencies at the following addresses: Army: Ms. Veronica Rines, Office of the Assistant Chief of Staff for Installation Management, Department of Army, Room 5A128, 600 Army Pentagon, Washington, DC 20310, (571) 256–8145; COE: Mr. Scott Whiteford, Army Corps of Engineers, Real Estate, CEMP–CR, 441 G Street NW., Washington, DC 20314; (202) 761–5542; (These are not toll-free numbers). Dated: September 19, 2013. Mark Johnston, Deputy Assistant Secretary for Special Needs. TITLE V, FEDERAL SURPLUS PROPERTY PROGRAM FEDERAL REGISTER REPORT FOR 09/27/2013 Suitable/Available Properties Building Arkansas Beaver Reservoir Operational Facility 2256/2258 N. 2nd Street Rogers AR 72756 Landholding Agency: COE Property Number: 31201330006 Status: Unutilized Directions: 2256 (1,750 sq. ft.); 2258 (1,430 sq. ft) Comments: Off-site removal only; no future agency use; residential; fair conditions; contact COE for more info. Unsuitable Properties Building Kentucky 875 Fort Campbell Fort Campbell KY 42223 Landholding Agency: Army Property Number: 21201330059 Status: Unutilized Directions: Only building 875 has the 20-day holding period from the Sept. 27 FR Comments: Public access denied & no alternative to gain access w/out compromising nat’l security. Reasons: Secured Area [FR Doc. 2013–23341 Filed 9–26–13; 8:45 am] BILLING CODE 4210–67–P E:\FR\FM\27SEN1.SGM 27SEN1

Agencies

[Federal Register Volume 78, Number 188 (Friday, September 27, 2013)]
[Notices]
[Pages 59708-59709]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23528]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Commercialization License: The Use 
of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and 
Hepatocellular Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 
404, indicates that the National Institutes of Health, Department of 
Health and Human Services, is contemplating the grant of an exclusive 
commercialization license to practice the inventions embodied in 
technology family E-219-2013/0, including U.S. patent application 61/
814,010 entitled ``A Novel Role of Cysteamine in Suppression of Cancer 
Invasion and Metastasis and Prolonging Survival of Host Through 
Inhibition of Matrix Metalloproteinases in Human Cancer'' [HHS Ref. E-
219-2013/0-US-01], Canadian patent application 2,813,514 entitled ``Use 
of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases'' 
[HHS Ref. E-219-2013/0-CA-02], South Korean patent application 10-2013-
43713 entitled ``Use of Cysteamine and Derivatives Thereof to Suppress 
Tumor Metastases''[HHS Ref. E-219-2013/0-KR-03], Australian patent 
application 2013205350 entitled ``Use of Cysteamine and Derivatives 
Thereof to Suppress Tumor Metastases'' [HHS Ref. E-219-2013/0-AU-04], 
and Mexican patent application MX/a/2013/004423 entitled ``Use of 
Cysteamine and Derivatives Thereof to Suppress Tumor Metastases'' [HHS 
Ref. E-219-2013/0-MX-05]; and all related continuing and foreign 
patents/patent applications for these technology families, to Raptor 
Pharmaceuticals, Inc. The patent rights in these inventions have been 
assigned to and/or exclusively licensed to the Government of the United 
States of America.
    The prospective exclusive commercialization license territory may 
be worldwide, and the field of use may be limited to:
    The treatment of pancreatic cancer, breast cancer and 
hepatocellular carcinoma (HCC) by using compositions containing 
cysteamine.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 28, 2013 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
commercialization license should be directed to: David A. Lambertson, 
Ph.D., Senior Licensing and Patenting Manager, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4632; 
Facsimile: (301) 402-0220; Email: lambertsond@mail.nih.gov.

SUPPLEMENTARY INFORMATION: Cysteamine is a naturally occurring 
degradation product of the amino acid cysteine that is most commonly 
used for the treatment of cystinosis. The inventors on this technology 
have demonstrated that cysteamine suppresses the activity of matrix 
metalloproteinases (MMPs), enzymes that have been implicated in tumor 
invasion and metastasis. Importantly, administration of cysteamine was 
able to reduce invasion and metastasis in mouse xenograft tumor models 
for pancreatic cancer, prolonging the survival of the mice while having 
no adverse side effects. Based on these findings, cysteamine could 
represent a novel therapeutic treatment of cancer with fewer side-
effects than current therapies.
    The prospective exclusive commercialization license will comply 
with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The 
prospective exclusive license may be granted unless the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR part 404 within thirty (30) days from the date of this 
published notice.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive license. Comments and objections

[[Page 59709]]

submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: September 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-23528 Filed 9-26-13; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.